H. Lundbeck AS - Company Profile
Powered by 
All the sales intelligence you need on H. Lundbeck AS in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how H. Lundbeck AS fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with H. Lundbeck AS.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, carries out the research, development, manufacturing, and marketing of pharmaceuticals for the treatment of central nervous system (CNS) diseases including psychiatric and neurological disorders. The company's products are indicated for the treatment of Alzheimer's disease, schizophrenia, alcohol dependence, migraine, depression, Parkinson's disease, anxiety, bipolar I disorder, depression, anxiety, psychosis and epilepsy, among others. It operates production facilities in Denmark, Italy, and France, and research centers in the US and Denmark. Lundbeck sells its products primarily to pharmaceutical distributors, pharmacies, and hospitals in the US, China, Spain, Canada, Italy, France, Australia, Brazil, South Korea, and the UK, and other countries. Lundbeck is headquartered in Valby, Denmark.
Headquarters
Denmark
Address
Ottiliavej 9, 2500 Valby, 2500
Website
www.lundbeck.com
Telephone
45 36301311
No of Employees
5,000
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HLUN A (CPH)
Revenue (2024)
$3.7B
11.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1.6%
(2024 vs 2023)
Market Cap*
$6.3B
Net Profit Margin (2024)
XYZ
-9.2%
(2024 vs 2023)
* As of and is in US$
H. Lundbeck AS premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pharmaceuticals: | Rxulti |
| Disease Areas: | Eptinezumab |
| Alzheimer's Disease | Ebixa |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In June, the company signed a partnership with Cradle to support Lundbeck in discovering and optimizing biotherapeutics that ultimately can improve patient outcomes. |
| 2026 | Others | In May, the company received orphan drug designation (ODD) in Japan by the Ministry of Health, Labour and Welfare (MHLW) for asedebart (Lu AG13909) for the treatment of patients with congenital adrenal hyperplasia (CAH) and Cushing’s disease (CD). |
| 2026 | Regulatory Approval | In May, the company received approval from South Korea’s Ministry of Food and Drug Safety for Vyepti. |
Competitor Comparison
| Key Parameters | H. Lundbeck AS | Novo Nordisk AS | Viatris Inc | Orifarm Group A/S | Leo Pharma AS |
|---|---|---|---|---|---|
| Headquarters | Denmark | Denmark | United States of America | Denmark | Denmark |
| City | Valby | Bagsvaerd | Canonsburg | Odense | Ballerup |
| State/Province | - | - | Pennsylvania | - | - |
| No. of Employees | 5,000 | 64,974 | 30,000 | 2,212 | 4,265 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Dorothea Wenzel | Chair | Executive Board | 2025 | 57 |
| Charl van Zyl | Chief Executive Officer; President | Senior Management | 2023 | 59 |
| Joerg Hornstein | Chief Financial Officer; Executive Vice President - Corporate functions | Senior Management | 2022 | 49 |
| Markus Kede | Chief AI Officer; Senior Vice President | Senior Management | 2026 | - |
| Lene Skole-Sorensen | Deputy Chairman | Executive Board | 2015 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer